HK1207983A1 - 包含抗 適體和 拮抗劑的組合物 - Google Patents

包含抗 適體和 拮抗劑的組合物

Info

Publication number
HK1207983A1
HK1207983A1 HK15108671.2A HK15108671A HK1207983A1 HK 1207983 A1 HK1207983 A1 HK 1207983A1 HK 15108671 A HK15108671 A HK 15108671A HK 1207983 A1 HK1207983 A1 HK 1207983A1
Authority
HK
Hong Kong
Prior art keywords
pdgf
vegf
compositions
aptamer
antagonist
Prior art date
Application number
HK15108671.2A
Other languages
English (en)
Inventor
Byeong Seon Chang
Richard Everett
Original Assignee
Ophthotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophthotech Corp filed Critical Ophthotech Corp
Publication of HK1207983A1 publication Critical patent/HK1207983A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK15108671.2A 2012-06-01 2015-09-06 包含抗 適體和 拮抗劑的組合物 HK1207983A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654672P 2012-06-01 2012-06-01
US201361778208P 2013-03-12 2013-03-12
PCT/US2013/043536 WO2013181495A2 (en) 2012-06-01 2013-05-31 Compositions comprising an anti-pdgf aptamer and a vegf antagonist

Publications (1)

Publication Number Publication Date
HK1207983A1 true HK1207983A1 (zh) 2016-02-19

Family

ID=49674074

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108671.2A HK1207983A1 (zh) 2012-06-01 2015-09-06 包含抗 適體和 拮抗劑的組合物

Country Status (18)

Country Link
US (1) US20150182623A1 (zh)
EP (1) EP2854844A4 (zh)
JP (1) JP2015519373A (zh)
KR (1) KR20150033620A (zh)
CN (1) CN104619335A (zh)
AR (1) AR091237A1 (zh)
AU (1) AU2013267310A1 (zh)
CA (1) CA2874412A1 (zh)
CL (1) CL2014003233A1 (zh)
CO (1) CO7240393A2 (zh)
EA (1) EA201492289A1 (zh)
HK (1) HK1207983A1 (zh)
IL (1) IL235797A0 (zh)
MX (1) MX2014014445A (zh)
PH (1) PH12014502577A1 (zh)
SG (1) SG11201407981RA (zh)
TW (1) TW201400122A (zh)
WO (1) WO2013181495A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160030396A (ko) 2013-07-12 2016-03-17 옵쏘테크 코포레이션 안과적 질환을 치료하거나 예방하기 위한 방법
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016025313A1 (en) * 2014-08-11 2016-02-18 Samir Patel Methods for treating or preventing ophthalmological conditions
CN112656939B (zh) * 2014-09-22 2023-12-08 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
RU2699544C2 (ru) 2015-01-28 2019-09-06 Пфайзер Инк. Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF)
CN105806830B (zh) * 2015-12-10 2019-01-29 北京联众泰克科技有限公司 一种稳定的hrp酶促化学发光底物液、其制备方法及应用
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CA3010623A1 (en) * 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases
US20190046642A1 (en) * 2016-02-23 2019-02-14 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
EP3541365A1 (en) * 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
JP7183268B2 (ja) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
EP3870145A1 (en) * 2018-10-26 2021-09-01 Amgen Inc. Formulations comprising a tris buffer and a protein
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021125852A1 (ko) * 2019-12-17 2021-06-24 주식회사 프로젠 신규 주사제 제형
WO2021175175A1 (zh) * 2020-03-04 2021-09-10 上海复宏汉霖生物技术股份有限公司 一种包含贝伐珠单抗的药物配制剂
WO2022019721A1 (ko) * 2020-07-24 2022-01-27 (주) 팬젠 안과용 액상 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
PT2364691E (pt) * 2006-06-16 2013-05-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
JP2013539364A (ja) * 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用

Also Published As

Publication number Publication date
TW201400122A (zh) 2014-01-01
CN104619335A (zh) 2015-05-13
EA201492289A1 (ru) 2015-05-29
AU2013267310A1 (en) 2014-12-11
EP2854844A4 (en) 2016-11-23
WO2013181495A2 (en) 2013-12-05
IL235797A0 (en) 2015-01-29
MX2014014445A (es) 2015-08-14
WO2013181495A3 (en) 2014-02-13
EP2854844A2 (en) 2015-04-08
AR091237A1 (es) 2015-01-21
CO7240393A2 (es) 2015-04-17
CL2014003233A1 (es) 2015-06-19
CA2874412A1 (en) 2013-12-05
US20150182623A1 (en) 2015-07-02
JP2015519373A (ja) 2015-07-09
PH12014502577A1 (en) 2015-01-21
KR20150033620A (ko) 2015-04-01
SG11201407981RA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
HK1207983A1 (zh) 包含抗 適體和 拮抗劑的組合物
IL244599A0 (en) Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
ZA201503146B (en) Il-6 antagonists and uses thereof
EP2922861A4 (en) BIOMARKER COMPOSITIONS AND METHODS
HK1185329A1 (zh) 建造電梯的方法和電梯配置
EP2823306A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2918315A4 (en) ARROW GAME
EP2816453A4 (en) TOUCH TYPE INPUT TERMINAL
GB2504570B (en) Microtome having an auto-rocking mode
GB201317376D0 (en) Viral load testing
EP2835904A4 (en) DEVICE FOR IMPROVING THE ENDURANCE OF A TERMINAL AND CORRESPONDING TERMINAL
SG2013091848A (en) An elevator
GB201217275D0 (en) Automated detection of harmful content
PL2671662T3 (pl) Urządzenie do zgrzewania rezystancyjnego
EP2899814A4 (en) THICK HEADED
GB2501396B (en) Muscle-training pant
ZA201504845B (en) Trampolines
EP2894722A4 (en) THICK HEADED
HK1197563A1 (zh) 負載試驗機
EP2942017A4 (en) SPARK PLUG FOR USE WITH A CLAMP DEVICE AND CLAMP DEVICE
SG2013067103A (en) Testing a fuse
GB2508174B (en) Detecting application behavior
GB201221341D0 (en) Pallets
EP2921248A4 (en) WELD STRUCTURE AND MACHINERY
PT2601214T (pt) Composições de antagonistas de vegf e utilizações destes